8-K ·Filed May 15, 2026
CD

CDTTW

CDT Equity Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001493152-26-023707
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

The temporary nature limits near-term dilution but signals reliance on external financing. Watch for further 8-Ks after May 31 for reinstatement of original terms or new funding arrangements.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+20d
CDTTW ▲ +125.76% at T+20d
NEUTRAL call ✓ call won +125.76% · α vs SPY +124.18% · entry $0.006600 → $0.0149
Next anchor: T+60d due 7w ago
Latest observation: T+32 +1.48% FF3 residual α
Entry anchored
May 15, 2026
via day open
T+1d
0.00%
call 0.00% · α +0.65%
$0.006600
settled 5mo ago
T+5d
0.00%
call 0.00% · α -1.62%
$0.006600
settled 4mo ago
T+20d
+125.76%
call +125.76% · α +124.18%
$0.0149
settled 4mo ago
T+60d
—
call — · α —
—
due 7w ago

Price Chart

Loading chart...

Executive Summary

CDT Equity Inc. entered temporary amendments to its equity line of credit and convertible note, capping regular ELOC purchases at $510,000 and reducing mandatory note prepayments to 10% of future capital raises. Both amendments expire on May 31, 2026.

Key Facts

  • ELOC regular purchase price capped at $510,000 without purchaser consent (Amendment No. 2).
  • Note mandatory prepayment reduced to 10% of gross proceeds from future financings, up from 100% (Note Amendment).
  • Both amendments effective only through May 31, 2026.

Financial Impact

Max ELOC draw per regular purchase $510,000; 10% of future raises goes to note rather than 100%.

dilutiondebt

Risk Factors

  • Post-expiry return to potentially more dilutive ELOC terms.
  • Continued dependence on institutional investor (Ascent Partners) for liquidity.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-023707
Exhibit: ex10-1.htm0001493152-26-023707
Exhibit: ex10-2.htm0001493152-26-023707
Document: 0001493152-26-023707-index-headers.html0001493152-26-023707
Document: 0001493152-26-023707-index.html0001493152-26-023707
Document: 0001493152-26-023707.txt0001493152-26-023707
3 reports for CDTTW
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CDTTW — sortable, filterable
TypeNow
May 15, 2026
20w ago
8-K
NEUTRAL ★ 3/10
$0.006600 $0.0149▲ +125.76%▲ +124.18%—
May 4, 2026
21w ago
EFFECT
BEARISH ★ 6/10
$0.006600 $0.006600· 0.00%▲ +5.65%—
Apr 22, 2026
23w ago
S-3
BEARISH ★ 7/10
$0.006600 $0.006600· 0.00%▲ +3.17%—
Showing 3 of 3

US Market Status

Market Closed — Opens Mon (37h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access